ArticleCardiovascular diabetology2025

Benefits of glucagon-like peptide-1 receptor agonists versus pioglitazone for cardio-hepatic outcomes: a territory-wide target trial emulation.

Lanlan Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.